Brief: Pila Pharma Candidate Molecule Receives Orphan Drug Designation In U.S.

Pila Pharma AB

15/07/2022 15:05

July 15 (Reuters) - Pila Pharma AB  PILA.ST :
    * CANDIDATE MOLECULE IS GRANTED ORPHAN DRUG DESIGNATION STATUS IN THE USA
    * US FOOD AND DRUG ADMINISTRATION, FDA, HAS GRANTED ORPHAN DRUG DESIGNATION (ODD) OF
DEVELOPMENT
CANDIDATE XEN-D0501 FOR TREATMENT OF ERYTHROMELALGIA, A RARE DISEASE THAT CAUSES EPISODES OF
BURNING PAIN AND REDNESS DUE TO NEUROGENIC INFLAMMATION.

Source text for Eikon:  ID:nBQN1rMsjt 
Further company coverage:  PILA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))